ADC Therapeutics SA宣布,在控制权变更的情况下,收购方将继续向医疗保健特许权公司支付特许权使用费,直至达到原始约定的上限金额。这一安排确保了特许权收益的持续性,不受公司所有权结构变化的影响。
ADC Therapeutics SA宣布,在控制权变更的情况下,收购方将继续向医疗保健特许权公司支付特许权使用费,直至达到原始约定的上限金额。这一安排确保了特许权收益的持续性,不受公司所有权结构变化的影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.